Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

WP1066

Small molecule · Inhibitor of STAT3

Phase 2 Most advanced trial
1 Registered trials

What is WP1066?

WP1066 is an orally bioavailable small molecule inhibitor of STAT3 that blocks intranuclear translocation of phosphorylated STAT3, suppressing STAT3 signaling and downstream c-Myc production. It upregulates costimulatory molecules on microglia and reverses immune suppression mediated by glioma cancer stem cells. WP1066 is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
STAT3
Mechanism
Inhibitor of STAT3
Pathways
STAT3 signaling, c-Myc regulation
Therapy area
Oncology
In trials of
MBRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
63V8AIE65T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05879250 Phase 2 Glioblastoma, IDH-Wildtype Recruiting MBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma, IDH-WildtypeMGMT-Unmethylated Glioblastoma

Other drugs acting on STAT3

IMX-110 Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.